Atea Pharmaceuticals has been granted a patent for a method using purine nucleotide phosphoramidates to treat or prevent COVID-19 caused by SARS-CoV-2. The compound of Formula I is administered in an effective amount to the human host. GlobalData’s report on Atea Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Atea Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Atea Pharmaceuticals, Recombinant AAV gene therapy was a key innovation area identified from patents. Atea Pharmaceuticals's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of covid-19 using purine nucleotide phosphoramidates

Source: United States Patent and Trademark Office (USPTO). Credit: Atea Pharmaceuticals Inc

A recently granted patent (Publication Number: US11813278B2) discloses a method for treating COVID-19 caused by the SARS-CoV-2 virus in human hosts. The method involves administering a compound of Formula I, with specific configurations and substituents, to the patient. The compound can be in various dosage forms suitable for oral, intravenous, or parenteral administration, including solid dosage forms like tablets or capsules, as well as liquid forms like solutions or suspensions.

Furthermore, the method outlines specific dosing regimens, including administering the compound for at least one week or about five days, with variations in frequency ranging from once a day to three times a day. The dosage amount is also specified, with at least about 500 mg or 550 mg of the compound being administered, either alone or as a hemisulfate salt, depending on the specific embodiment. Overall, the patent provides detailed guidance on the treatment of COVID-19 using the disclosed compound of Formula I, emphasizing different administration options and dosing parameters for optimal efficacy.

To know more about GlobalData’s detailed insights on Atea Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies